Glenmark Pharmaceuticals Ltd (GLENMARK):企業の財務・戦略的SWOT分析

◆英語タイトル:Glenmark Pharmaceuticals Ltd (GLENMARK) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C15440
◆発行会社(調査会社):GlobalData
◆発行日:2019年3月
◆ページ数:54
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Glenmark Pharmaceuticals Ltd (GLENMARK) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Glenmark Pharmaceuticals Ltd (Glenmark) focuses on the discovery of new chemical entities (NCEs) and new biological entities (NBEs). The company’s formulations business encompasses therapeutic areas such as dermatology, anti-infective, respiratory, central nervous system, and oncology. It also offers a wide range of generic products. The company manufactures and supplies active pharmaceutical ingredients (APIs). Glenmark developed a proprietary platform, Bispecific Engagement by antibodies based on the T-cell receptor (BEAT) for production of bispecific antibodies. The company markets its products in North America, South America, Asia-Pacific and Africa.

Glenmark Pharmaceuticals Ltd Key Recent Developments

Mar 06,2019 Glenmark Pharmaceuticals appoints Alessandro Riva as CEO of its new innovation company
Feb 15,2019 Glenmark Pharmaceuticals to establish new company in US
Feb 14,2019 Glenmark’s consolidated revenue rises 15.95% to Rs. 25,550.45 Mn. in Q3 FY 2018 – 19
Dec 19,2018 Glenmark Pharmaceuticals announces entry into branded dermatology segment in the United States

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Glenmark Pharmaceuticals Ltd – Key Facts
Glenmark Pharmaceuticals Ltd – Key Employees
Glenmark Pharmaceuticals Ltd – Key Employee Biographies
Glenmark Pharmaceuticals Ltd – Major Products and Services
Glenmark Pharmaceuticals Ltd – History
Glenmark Pharmaceuticals Ltd – Company Statement
Glenmark Pharmaceuticals Ltd – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Glenmark Pharmaceuticals Ltd – Business Description
Product Category: Other Operating Revenue
Performance
Product Category: Sale of Products
Performance
Product Category: Sale of Services
Performance
Geographical Segment: Europe
Performance
Geographical Segment: India
Performance
Geographical Segment: Latin America
Performance
Geographical Segment: Rest of the World (ROW)
Performance
Geographical Segment: USA
Performance
R&D Overview
Glenmark Pharmaceuticals Ltd – Corporate Strategy
Glenmark Pharmaceuticals Ltd – SWOT Analysis
SWOT Analysis – Overview
Glenmark Pharmaceuticals Ltd – Strengths
Glenmark Pharmaceuticals Ltd – Weaknesses
Glenmark Pharmaceuticals Ltd – Opportunities
Glenmark Pharmaceuticals Ltd – Threats
Glenmark Pharmaceuticals Ltd – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Glenmark Pharmaceuticals Ltd, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 06, 2019: Glenmark Pharmaceuticals appoints Alessandro Riva as CEO of its new innovation company
Feb 15, 2019: Glenmark Pharmaceuticals to establish new company in US
Feb 14, 2019: Glenmark’s consolidated revenue rises 15.95% to Rs. 25,550.45 Mn. in Q3 FY 2018 – 19
Dec 19, 2018: Glenmark Pharmaceuticals announces entry into branded dermatology segment in the United States
Nov 13, 2018: Glenmark’s consolidated revenue rises 14.39% to Rs. 25,813.32 Mn. in Q2 FY 2018–19
Nov 07, 2018: Glenmark Pharmaceuticals Announces Decision to Launch Phase 1 Trial in Solid Tumors for its CD38xCD3 Bispecific Antibody GBR 1342 Based on Human Translational Data
Oct 30, 2018: Glenmark Pharmaceuticals celebrates the inauguration of its U.S. manufacturing site in Monroe, North Carolina
Oct 18, 2018: Data on Glenmark Pharmaceuticals” GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody in Development for the Treatment of Moderate-to-Severe Atopic Dermatitis, to be Presented at the Fall Clinical Dermatology Conference
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Glenmark Pharmaceuticals Ltd, Key Facts
Glenmark Pharmaceuticals Ltd, Key Employees
Glenmark Pharmaceuticals Ltd, Key Employee Biographies
Glenmark Pharmaceuticals Ltd, Major Products and Services
Glenmark Pharmaceuticals Ltd, History
Glenmark Pharmaceuticals Ltd, Other Locations
Glenmark Pharmaceuticals Ltd, Subsidiaries
Glenmark Pharmaceuticals Ltd, Key Competitors
Glenmark Pharmaceuticals Ltd, Ratios based on current share price
Glenmark Pharmaceuticals Ltd, Annual Ratios
Glenmark Pharmaceuticals Ltd, Annual Ratios (Cont...1)
Glenmark Pharmaceuticals Ltd, Annual Ratios (Cont...2)
Glenmark Pharmaceuticals Ltd, Interim Ratios
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Glenmark Pharmaceuticals Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Glenmark Pharmaceuticals Ltd, Performance Chart (2014 - 2018)
Glenmark Pharmaceuticals Ltd, Ratio Charts
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Glenmark Pharmaceuticals Ltd (GLENMARK):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Korea Zinc Co Ltd (010130):企業の財務・戦略的SWOT分析
    Summary Korea Zinc Co Ltd (Korea Zinc) operates as a mineral smelting company. The company develops and acquires gold, silver, cobalt, zinc, and copper and other rare and base metal properties. It operates a production facility, Onsan Refinery in Ulju-gun region of Ulsan in South Korea. Korea Zinc’s …
  • Ashok Leyland Limited:企業のM&A・事業提携・投資動向
    Ashok Leyland Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Ashok Leyland Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • Luna Innovations Inc (LUNA):企業の財務・戦略的SWOT分析
    Summary Luna Innovations Inc (Luna) is an optical technology development company that research, develops and commercializes speed optics and fiber optic test products. The company provides products such as fiber optic sensing products, fiber optic test and measurement products, high speed optical pr …
  • Edgewell Personal Care LLC (EPC):企業の財務・戦略的SWOT分析
    Edgewell Personal Care LLC (EPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • DexCom Inc (DXCM)-医療機器分野:企業M&A・提携分析
    Summary DexCom Inc (DexCom) is a medical device company that performs design, development and commercialization of continuous glucose monitoring systems for ambulatory and in-hospital use. The company’s major products include DexCom G4, DexCom G4 Platinum and other continuous glucose monitoring syst …
  • Miltenyi Biotec GmbH:医療機器:M&Aディール及び事業提携情報
    Summary Miltenyi Biotec GmbH (Miltenyi) is a biotechnology company that offers biomedical research and cellular therapy products for cell isolation, flow cytometry, sample preparation and cell culture. The company offers sample preparation, cell separation, flow cytometry, cell culture and stimulati …
  • Enbridge Energy Partners LP (EEP):企業の財務・戦略的SWOT分析
    Enbridge Energy Partners LP (EEP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Elron Electronic Industries Ltd (ELRNF):医療機器:M&Aディール及び事業提携情報
    Summary Elron Electronic Industries Ltd (Elron), a subsidiary of IDB Holding Corp Ltd, is a provider of medical device and cyber technology solutions. The company offers development of patient care systems for stroke care, microbiology, age-related macular degeneration, orthopedics, and heart diseas …
  • GKN Aerospace Services Ltd:企業の戦略的SWOT分析
    GKN Aerospace Services Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Taseko Mines Limited:企業の戦略・SWOT・財務情報
    Taseko Mines Limited - Strategy, SWOT and Corporate Finance Report Summary Taseko Mines Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Atlantic Power Corporation:発電所・企業SWOT分析
    Atlantic Power Corporation - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key em …
  • Holland America Line Inc:企業の戦略的SWOT分析
    Holland America Line Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • The Gunma Bank Ltd:企業の戦略・SWOT・財務分析
    The Gunma Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary The Gunma Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Lepu Medical Technology (Beijing) Co Ltd (300003):製薬・医療:M&Aディール及び事業提携情報
    Summary Lepu Medical Technology (Beijing) Co Ltd (Lepu Medical) is a medical technology company that offers medical equipments, pharmaceutical products and healthcare services. The company’s products include cardiovascular interventional products, surgical cardiology products, peripheral interventio …
  • Samsung Heavy Industries Co., Ltd.:企業の戦略・SWOT・財務分析
    Samsung Heavy Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Samsung Heavy Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Orascom Development Egypt Sae
    Orascom Development Egypt Sae - Strategy, SWOT and Corporate Finance Report Summary Orascom Development Egypt Sae - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Attijari Bank SA:企業の戦略・SWOT・財務分析
    Attijari Bank SA - Strategy, SWOT and Corporate Finance Report Summary Attijari Bank SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Lyka Labs Ltd (LYKALABS):企業の財務・戦略的SWOT分析
    Summary Lyka Labs Ltd (Lyka Labs) is a manufacturer of pharmaceutical formulations and active pharmaceutical ingredients. The company provides formulations such as lyophilized injections, topical formulations of cream, ointment, foams, gels and lotions. It offers formulation research and development …
  • Tempo Beverages Ltd.:企業の戦略・SWOT・財務情報
    Tempo Beverages Ltd. - Strategy, SWOT and Corporate Finance Report Summary Tempo Beverages Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Zynex Inc (ZYXI):企業の財務・戦略的SWOT分析
    Summary Zynex Inc (Zynex) formerly Zynex Medical Inc operates as a medical technology company that designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. The company’s products include NexWave, a dual channel, multi-modality interferential curr …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆